Back to Shop
On Backorder
BPC-157 + TB-500

BPC-157 + TB-500

$165.00

Back Order

Processing time is 8–21 calendar days.

BPC-157 + TB-500 lyophilised research peptide in Australia, supplied for in-vitro laboratory investigation. Combined research blend pairing the gastric-derived pentadecapeptide BPC-157 and the 43-residue acetylated thymosin-beta-4 analogue TB-500 in a single co-lyophilised vial. ≥99% purity by HPLC, third-party Certificate of Analysis available. Dispatched within 1-3 business days. Research use only. Not for human consumption, therapeutic use, or diagnostic application.

Buy more, Save more

Buy 1 Standard —
Buy 2 Save 5% —
Buy 3 Save 10% —
Buy 4 Save 15% —
Product details

Research Context

This stack pairs two extensively examined research peptides in a single lyophilised vial: BPC-157 (Body Protection Compound-157), a 15-residue partial sequence from a mammalian gastroprotective protein, and TB-500, a 43-residue acetylated synthetic peptide corresponding to the active region of Thymosin Beta-4. Both belong to distinct mechanistic families: BPC-157 is a pentadecapeptide fragment with no known endogenous full-length precursor, while TB-500 derives from a naturally occurring actin-sequestering protein expressed broadly across mammalian tissues. The combination is supplied as a co-lyophilised blend for in-vitro investigation of overlapping repair pathways.

Preclinical literature has examined BPC-157 in models of angiogenic signalling, nitric oxide pathway modulation, and extracellular matrix remodelling, while TB-500 has been studied in models of cellular migration, actin cytoskeleton dynamics, and tissue regeneration. The stack format allows researchers to evaluate combined exposure effects in parallel with single-compound controls. All references are to published in-vitro and ex-vivo studies; this product is not characterised for therapeutic use.

Chemistry & Structural Modification

The stack contains two distinct peptides in a single vial, each retaining its native synthesis chemistry. Component identification and reference data are listed below.

  • BPC-157: 15-residue pentadecapeptide, sequence GEPPPGKPADDAGLV. Molecular formula C62H98N16O22, molecular weight 1419.5 g/mol. CAS 137525-51-0. PubChem CID 9941957.
  • TB-500 (Thymosin Beta-4): 43-residue acetylated peptide, sequence Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES-OH. Molecular formula C212H350N56O78S, molecular weight 4963.4 g/mol. CAS 77591-33-4. PubChem CID 16132341.
  • Blend composition: 10 mg BPC-157 + 10 mg TB-500 per 20 mg vial.

Lyophilisation & Stability

Co-lyophilised under standard conditions to produce a stable filler-free powder. The freeze-dried format supports extended shelf life when stored under recommended conditions and is the conventional presentation for laboratory peptide stacks.

Storage

Store lyophilised vial at 2 to 8°C, protected from light. (Long-term storage at −20°C is standard practice.)

Reconstituted solution: 2 to 8°C, used within 14 to 30 days. Avoid repeated freeze-thaw cycles.

Quality & Documentation

  • Purity: ≥99% by HPLC (each component)
  • Certificate of Analysis (COA): published on our COA page.

Related products